The A/T1381 polymorphism in the A1-domain of von Willebrand factor influences the affinity of von Willebrand factor for platelet glycoprotein Ibα

Summary

Many polymorphisms in vonWillebrand factor (VWF) have been reported and their association with VWF plasma levels or cardiovascular diseases has been investigated. The aim of this study was to examine whether the amino acid polymorphis mA/T1381 in the VWF A1-domain would affect VWF binding to platelet GPIbα. Sixty-one normal individuals were genotyped at the A/T1381 locus. Twenty-one A/A1381 homozygotes, 30 A/T1381 heterozygotes and 10 T/T1381 homozygotes were identified. Remarkably, when compared to VWF of A/T1381 and A/A1381 individuals, VWF of individuals carrying the T/T1381 variant showed an increased affinity for its platelet receptor GPIbα under static conditions, as reflected by an increased sensitivity to low concentrations of ristocetin or botrocetin. In addition, also the rVWF-T1381 demonstrated a higher affinity for GPIbα than rVWF-A1381. Interestingly, this enhanced affinity of the T/T variant over the A/T and A/A variant was, however, too subtle to affect platelet adhesion under physiological flow conditions, which fully corroborates the normal haemostatic phenotype of all individuals. We demonstrate that the VWF A/T1381 polymorphism plays an important role in inter-individual variability of the affinity of VWF for GPIbα, with T/T variants having a higher affinity than A/A and A/T variants, at least under static conditions in vitro. Further genetic linkage and association studies are necessary to establish whether the A/T1381 polymorphism could correlate with an increased risk of thrombotic events.

Keywords

von Willebrand factor - platelet glycoprotein Ibα - A/T1381 polymorphism - vonWillebrand disease - thrombosis

• References

• 1 Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-1234.
• 2 Mayadas TN, Wagner DD. Von Willebrand factor biosynthesis and processing. Ann NY Acad Sci 1991; 614: 153-166.
• 3 Savage B. et al. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84: 289-297.
• 4 Ruggeri ZM. Von Willebrand factor. Curr Opin Hematol 2003; 10: 142-149.
• 5 Siedlecki CA. et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
• 6 Howard MA, Firkin BG. Ristocetin-a new tool in the investigation of platelet aggregation. Thromb Diath Haemorrh 1971; 26: 362-369.
• 7 Read MS. et al. Role of botrocetin in platelet agglutination: formation of an activated complex of botrocetin and von Willebrand factor. Blood 1989; 74: 1031-1035.
• 8 De Lange M. et al. Genetic influences on fibrinogen, tissue plasminogen activator-antigen and von Willebrand factor in males and females. Thromb Haemost 2006; 95: 414-419.
• 9 Soutu JC. et al. Genome-wide linkage analysis of von Willebrand factor plasma levels: results from the GAIT project. Thromb Haemost 2003; 89: 468-474.
• 10 Morelli VM. et al. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007; 97: 534-541.
• 11 Keightley AM. et al. Variation at the von Willebrand factor (VWF) gene locus is associated with plasma VWF:Ag levels: identification of three novel single nucleotide polymorphisms in the VWF gene promoter. Blood 1999; 93: 4277-4283.
• 12 Harvey PJ. et al. A single nucleotide polymorphism at nucleotide -1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF:Ag levels. Br J Haematol 2000; 109: 349-353.
• 13 van der Meer IM. et al. Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 2004; 124: 343-347.
• 14 Lacquemant C. et al. Association between high von Willebrand factor levels and the Thr789Ala vWF gene polymorphism but not with nephropathy in type I diabetes. The GENEDIAB Study Group and the DESIR Study Group. Kidney Int 2000; 57: 1437-1443.
• 15 Bowen DJ, Collins PW. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004; 103: 941-947.
• 16 Donner M. et al. An HphI-polymorphism in exon 28 of the von Willebrand factor gene, and its frequency among patients with various forms of von Willebrand’s disease. Br J Haematol 1991; 78: 403-407.
• 17 Vanhoorelbeke K. et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000; 83: 107-113.
• 18 Vanhoorelbeke K. et al. A reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. Semin Thromb Hemost 2002; 28: 161-166.
• 19 Vanhoorelbeke K. et al. Plasma glycocalicin as a source of GPlb alpha in the von Willebrand factor ristocetin cofactor ELISA. Thromb Haemost 2005; 93: 165-171.
• 20 Randi AM. et al. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposedplatelet glycoprotein Ib binding sequences. J Clin Invest 1991; 87: 1220-1226.
• 21 Ribba AS. et al. Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost 2001; 86: 848-854.
• 22 Mancuso DJ. et al. Structure of the gene for human von Willebrand factor. J Biol Chem 1989; 264: 19514-19527.
• 23 Vanhoorelbeke K. et al. A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal Anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction. J Biol Chem 2003; 278: 37815-37821.
• 24 Sixma JJ. et al. Effect of deletion of the A1 domain of von Willebrand factor on its binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem 1991; 196: 369-375.
• 25 Vanhoorelbeke K. et al. Sequence alignment between VWF and peptides inhibiting the VWF-collagen interaction does not result in the identification of a collagen-binding site in VWF. Thromb Haemost 2000; 84: 621-625.
• 26 Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981; 57: 1140-1143.
• 27 Miller JL. et al. Von Willebrand factor binds to platelets and induces aggregation in platelet-type but not type IIb von Willebrand disease. J Clin Invest 1983; 72: 1532-1542.
• 28 Ulrichts H. et al. A monoclonal antibody directed against human von Willebrand factor induces type 2B-like alterations. J Thromb Haemost 2004; 2: 1622-1628.
• 29 Ulrichts H. et al. Shielding of the A1 domain by the D’D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 2006; 281: 4699-4707.
• 30 Murata M. et al. Low shear stress can initiate von Willebrand factor-dependent platelet aggregation in patients with type IIb and platelet-type von Willebrand disease. J Clin Invest 1993; 92: 1555-1558.
• 31 Ajzenberg N. et al. Effect of recombinant von Willebrand factor reproducing type 2B or type 2M mutations on shear-induced platelet aggregation. Blood 2000; 95: 3796-3803.
• 32 Favaloro EJ. Laboratory identification of von Willebrand disease: technical and scientific perspectives. Semin Thromb Hemost 2006; 32: 456-471.
• 33 Casana P. et al. New mutations in exon 28 of the von Willebrand factor gene detected in patients with different types of von Willebrand’s disease. Haematologica 2001; 86: 414-419.
• 34 Hilbert L. et al. Identification of two mutations (Arg611Cys and Arg611His) in the A1 loop of von Willebrand factor (VWF) responsible fortype 2 von Willebrand disease with decreased platelet-dependent function of VWF. Blood 1995; 86: 1010-1018.
• 35 Matsushita T. et al. Localization of von Willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis. J Biol Chem 2000; 275: 11044-11049.
• 36 Bonnefoy A. et al. Shielding the front-strand beta 3 of the von Willebrand factor A1 domainin hibits its binding to platelet glycoprotein Ib alpha. Blood 2003; 101: 1375-1383.